……..catching up on FDA Approvals The FDA recently approved a new infused therapy, Avzivi (bevacizumab-tnjn) from Bio-Thera Solutions, as a biosimilar to AVASTIN (bevacizumab). It did not receive
The National Association of Specialty Pharmacy (NASP) recently released the results of a patient satisfaction survey of specialty pharmacies. The results are worth evaluating…… closely. Ultimately, satisfaction will
…… catching up o FDA approvals The FDA has approved a new specialty topical gel, Filsuvez (birch triterpenes) from Chiesi Farmaceutici S.p.A. Parma, indicated for
We’ve often written about the battle being fought around site-of-care. As we’ve suggested previously, it comes down to one word….. MONEY. Payers have been turning up
……………catching up on FDA approvals The FDA approved a new ORAL therapy, Fabhalta (iptacopan) from Novartis, the first oral monotherapy for the treatment of adults
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
Did you hear it too? We are talking about hearing the melody to the old Queen song….. Anther One Bites the Dust! The one biting the
……..catching up on FDA approvals The FDA recently approved a new ORAL therapy, Truqap (capivasertib) from AstraZeneca Pharmaceuticals (AZ), for co-administration with Faslodex (fulvestrant) for adult
……..catching up on FDA approvals The FDA approved a new ORAL therapy, Ogsiveo (nirogacestat) to SpringWorks Therapeutics Inc., for adult patients with progressing desmoid tumors
Let’s see if we can get your attention…… “The market structure we have right now—three big PBMs dominating the market—will probably not be the one
